Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation

Ken Okumura; Masaharu Akao; Tetsuro Yoshida; Masahito Kawata; Osamu Okazaki; Shintaro Akashi; Kenichi Eshima; Kimihiko Tanizawa; M. Fukuzawa; Takuya Hayashi; Masahiro Akishita; Professor Gregory Lip; Takeshi Yamashita

doi:10.1056/nejmoa2012883

Abstract

1 min read

In very elderly Japanese patients with nonvalvular atrial fibrillation who were not appropriate candidates for standard doses of oral anticoagulants, a once-daily 15-mg dose of edoxaban was superior to placebo in preventing stroke or systemic embolism and did not result in a significantly higher incidence of major bleeding than placebo. (Funded by Daiichi Sankyo; ELDERCARE-AF ClinicalTrials.gov number, NCT02801669.).

Related publications

Article2017

Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study

Ken Okumura, Professor Gregory Lip, Masaharu Akao, Kimihiko Tanizawa, M. Fukuzawa, Kenji Abe, Masahiro Akishita, Takeshi Yamashita

Article2021

Abstract 9030: Effects of Edoxaban on Clinical Outcomes in Extremely Elderly Patients (aged ≥ 90 Years) With Atrial Fibrillation: A Subanalysis of Data from the ELDERCARE-AF Trial

Masaru Kuroda, Eiji Tamiya, Takahisa Nose, Akiyoshi Ogimoto, Junki Taura, Yuki Imamura, M. Fukuzawa, Takuya Hayashi, Masaharu Akao, Takeshi Yamashita, Professor Gregory Lip, Ken Okumura

Article2021

Clinical Characteristics and Outcomes of Very Elderly Patients With Atrial Fibrillation at High Bleeding Risk　― The Fushimi AF Registry ―

Yuya Ide, Hisashi Ogawa, Kenjiro Ishigami, Syuhei Ikeda, Kosuke Doi, Yasuhiro Hamatani, Akiko Fujino, Yoshimori An, Mitsuru Ishii, Moritake Iguchi, Nobutoyo Masunaga, Masahiro Esato, Hikari Tsuji, Hiromichi Wada, Koji Hasegawa, Mitsuru Abe, Professor Gregory Lip, Masaharu Akao

Article2021

Stroke prevention with non-vitamin K antagonist oral anticoagulants in high risk elderly atrial fibrillation patients at increased bleeding risk

Tze‐Fan Chao, Professor Gregory Lip, S.A Chen

Article2024

Asundexian versus Apixaban in Patients with Atrial Fibrillation

Jonathan P. Piccini, Manesh R. Patel, Jan Steffel, Keith C. Ferdinand, Isabelle C. Van Gelder, Andrea M. Russo, Chang-Sheng Ma, Shaun G. Goodman, Jonas Oldgren, Christopher Hammett, Renato D. Lópes, Masaharu Akao, Raffaele De Caterina, Paulus Kirchhof, Diana A. Gorog, Martin E W Hemels, Michiel Rienstra, W. Schuyler Jones, Josephine Harrington, Professor Gregory Lip, Stephen J. Ellis, Frank W. Rockhold, Christoph Neumann, John H. Alexander,

Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation

Abstract

Discussion(0)

Related publications

Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study

Abstract 9030: Effects of Edoxaban on Clinical Outcomes in Extremely Elderly Patients (aged ≥ 90 Years) With Atrial Fibrillation: A Subanalysis of Data from the ELDERCARE-AF Trial

Clinical Characteristics and Outcomes of Very Elderly Patients With Atrial Fibrillation at High Bleeding Risk ― The Fushimi AF Registry ―

Stroke prevention with non-vitamin K antagonist oral anticoagulants in high risk elderly atrial fibrillation patients at increased bleeding risk

Asundexian versus Apixaban in Patients with Atrial Fibrillation

Clinical Characteristics and Outcomes of Very Elderly Patients With Atrial Fibrillation at High Bleeding Risk　― The Fushimi AF Registry ―